| Document |
Document Title |
|
WO/2022/170052A1 |
The present disclosure relates to compounds of Formula (I) or a stereoisomer, polymorph, hydrate, solvate, or pharmaceutically acceptable salt thereof. The present disclosure also relates to uses of the compounds, e.g., in treating or pr...
|
|
WO/2022/165796A1 |
Provided is a composition comprising a phenalkamine represented by formula (I). wherein, X is H or OH; R 1 is an aliphatic chain with more than 8 carbon atoms, R 2 is H, a C1-C10 alkyl, phenyl, or a C5-C6 cycloaliphatic group; R 3 and R ...
|
|
WO/2022/165427A1 |
A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or solvate thereof.
|
|
WO/2022/157633A1 |
The invention relates to enantiomerically pure desglymidodrine and process for preparation thereof. In particular, the invention relates to enantiomerically pure desglymidodrine or a pharmaceutically acceptable salt, solvate or a hydrate...
|
|
WO/2022/152109A2 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nuc...
|
|
WO/2022/133236A1 |
Forms of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobu
tyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]acetamid
e, designated herein as Compound I, were prepared and characterized in the solid state. Also provided are ...
|
|
WO/2022/113854A1 |
Provided is a fluorine-containing ether compound represented by the following formula. Formula: R1-CH2-R2-CH2-R3-CH2-R4-CH2-R5 (wherein: R3 represents a divalent organic group containing an alicyclic structure having 3-13 carbon atoms an...
|
|
WO/2022/110612A1 |
The present invention relates to the technical field of the synthetic preparation for medicines, and relates to a preparation method for an S-configuration phenylethylamine hydrochloride compound. The preparation method comprises the fol...
|
|
WO/2022/106452A2 |
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...
|
|
WO/2022/108984A1 |
The invention relates in particular to methods and intermediates for the synthesis of Compound 1 that inhibits MCL1 and is useful in the treatment of cancers.
|
|
WO/2022/102557A1 |
The present invention relates to: a compound represented by formula (I) (in the formula, X denotes -CH2- or -NH-; R1 and R3 each independently denote a substituted or unsubstituted hydrocarbon group having 5-30 carbon atoms, with any -CH...
|
|
WO/2022/100487A1 |
Disclosed is an amino-combretastatin derivative, and in particular a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of the pharmaceutically acceptable salt thereof...
|
|
WO/2022/100704A1 |
The present application relates to the field of electroluminescence, and disclosed are a compound, an organic electroluminescent apparatus and a display device. The structural formula of the compound is represented by formula (I). The or...
|
|
WO/2022/098940A1 |
The present disclosure relates to a method for producing a secondary amine or tertiary amine or mixture thereof in a single reaction step and the use of such amines in various applications including, but not limited to, polyurethane, oil...
|
|
WO/2022/090235A1 |
The invention relates to 2-methoxymethyl-p-phenylenediamine in cosmetic grade quality»and to methods for converting 2-methoxymethyl-p-phenylenediamine having an impurity degree non- acceptable for cosmetic applications to 2-methoxymethy...
|
|
WO/2022/087246A1 |
Disclosed herein are polymers formed by the condensation of bis(hydroxycarbyl)-aminophenolic compounds with aldehydes. The condensation polymers include one or more repeat units having bis(hydroxycarbyl)amino functionality. The polymers ...
|
|
WO/2022/087248A1 |
Disclosed herein are polymers formed by the condensation of bis(hydroxycarbyl)- aminophenolic compounds with aldehydes. The condensation polymers include one or more repeat units having bis(hydroxycarbyl)amino functionality. The hydroxyl...
|
|
WO/2022/079574A1 |
The present disclosure provides compositions and methods for reducing inflammation to improve or maintain mental health or physical health in an individual. In some aspects, the compositions include at least one 5HT2A agonist and at leas...
|
|
WO/2022/075396A1 |
[Problem] The purpose of the present invention is to provide a compound which is suitable for a low refractive index layer in a capping layer in order to improve the light extraction efficiency of an organic EL element. [Solution] The pr...
|
|
WO/2022/067446A1 |
Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and on...
|
|
WO/2022/065142A1 |
The present invention provides a method for producing a tertiary amine composition, said method comprising the steps (1) to (3) described below. Step (1): an amination reaction step wherein dimethyl amine and an aliphatic aldehyde or a...
|
|
WO/2022/058894A1 |
A fuel composition is described. The composition contains gasoline and an aryloxy alkylamine additive. The structure of the aryloxy alkylamine additive is given by Formula (I) where the aryloxy alkylamine additive is present in about 10 ...
|
|
WO/2022/039079A1 |
A fluorine-containing ether compound represented by formula (1). (1) R1-O-R2-CH2-R3-CH2-R4-R5 (in which R3 is a perfluoropolyether chain, R1 is a C2–8 alkenyl group or a C3–8 alkynyl group, R2 and R4 are each independently a bivalent...
|
|
WO/2022/023291A1 |
Method for the purification of vilanterol trifenatate It is provided a method for the purification of vilanterol trifenatate of formula (I) comprising crystallizing vilanterol trifenatate from a ketone solvent selected from the group con...
|
|
WO/2022/019369A1 |
The present invention relates to a method for preparing 4,4'-oxydianiline, comprising the steps of: obtaining a reactant containing dinitrodiphenyl ether by mixing and reacting nitrochlorobenzene and nitrophenolate salt under the presenc...
|
|
WO/2022/006186A1 |
Phenalkylamines and methods of treating mood disorders with phenalkylamines. Also provided are pharmaceutical compositions that include phenalkylamines.
|
|
WO/2021/260118A1 |
The invention relates to mixtures of propoxylated 4-toluidines containing two or more different di- or tri-propoxylated or higher propoxylated p-toluidines in specific weight ratios, to methods for preparing them and to their use as poly...
|
|
WO/2021/258159A1 |
The present invention relates to novel compounds which are capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are useful for treatment of a variety of neuromuscular d...
|
|
WO/2021/248770A1 |
A genetically encoded formaldehyde reactive unnatural amino acid. Specifically, the present invention relates to a genetically encoded formaldehyde reactive unnatural amino acid PrAK, a preparation method and an application thereof in de...
|
|
WO/2021/245504A1 |
The present invention relates to a process for the preparation of α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4
-dimethoxy-α-(1-methylethyl), monohydrochloride (verapamil hydrochloride, a compound of formula I), the proce...
|
|
WO/2021/227655A1 |
Provided are a compound, an organic electroluminescent device, and a display device. The compound has a structure as shown in formula I. The introduction of the substituent Ar2 at position 1 on a naphthalene ring can not only adjust the ...
|
|
WO/2021/224184A1 |
The present disclosure relates to methods for the production of the isomerically pure or isomerically enriched cis-clomiphene and salts thereof.
|
|
WO/2021/214727A1 |
Cancer stem cells are responsible for tumor recurrence, distant metastasis and drug-resistance, in the vast majority of cancer patients. There exists an urgent need to identify new mitochondrial inhibitor drugs that can target and eradic...
|
|
WO/2021/177219A1 |
Provided is a catalyst which can be used for enabling a reductive amination reaction under a low-temperature low-hydrogen-pressure condition, comprises cobalt supported on an oxide, and is characterized by being produced by a method incl...
|
|
WO/2021/168988A1 |
The present invention provides a synthesis method for a fluorine-containing chiral amine compound. The synthesis method comprises: reacting an amino donor with a fluorine-containing dihydroxy ketal compound under the catalysis of transam...
|
|
WO/2021/160654A1 |
This invention concerns a versatile and simple one-pot method to prepare nanomaterials, and in particular nanoparticles, grafted with an ultra-thin layer of calixarenes by placing at 5 least one oxidized metal with at least one calix[n]a...
|
|
WO/2021/147971A1 |
Provided in the present invention are a compound as shown in formula I, various crystal forms thereof, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition. The compound of the present inve...
|
|
WO/2021/148043A1 |
The present invention relates to the field of drugs, and particularly relates to a nitrophenyl ether compound having structural characteristics of a general formula (I), a stereoisomer, a metabolite, a metabolic precursor, a prodrug, a s...
|
|
WO/2021/132252A1 |
A fluorine-containing ether compound which is represented by the formula below. R1-R2-CH2-R3-CH2-R4-R5 (In the formula, R3 represents a perfluoropolyether chain; each of R1 and R5 independently represents any one of an optionally substit...
|
|
WO/2021/103327A1 |
The present invention relates to a preparation method for an aprepitant intermediate impurity. The preparation method comprises the following reaction steps: (A) carrying out a Grignard reaction on a raw material 1 and a Grignard reagent...
|
|
WO/2021/104547A1 |
The present invention relates to compounds of general formula (I) (I) wherein Cg is -CH2-C≡CH or -CH2-CH=CH2; R is independently selected from the group consisting of (Cl-C6)alkyl, which may be linear or branched; (C5-C6)cykloalkyl; R1...
|
|
WO/2021/093292A1 |
Disclosed is a co-production method for 2-(2-amino-propoxy)ethanol and polyether polyol. The method comprises the steps of: (1) performing a chain-linking reaction on ethylene glycol and propylene oxide to obtain a mixed product A; (2) a...
|
|
WO/2021/091222A1 |
The present application relates to a compound of chemical formula 1, a binder resin, a negative-type photosensitive resin composition, and a display device comprising a black bank formed using same.
|
|
WO/2021/081624A1 |
The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigm...
|
|
WO/2021/076944A1 |
Embodiments of a composition of the present invention for scavenging sulfides from hydrocarbon fluids and water generally include diaminol/diaminacetal provided in a chemical system, wherein the diaminol/diaminacetal is prepared by react...
|
|
WO/2021/065382A1 |
Provided is a fluorine-containing ether compound represented by formula (1). The fluorine-containing ether compound is characteristically represented by formula (1) below. (1): R1-R2-CH2-R3-CH2-R4 (R3 is a perfluoropolyether chain; R1 is...
|
|
WO/2021/058024A1 |
Provided are a class of heterospirocyclic compound which act as a lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in the preparation of a drug for treating diseases associated with LSD1. The heterospirocyclic compounds ...
|
|
WO/2021/059999A1 |
Provided is a liquid crystal aligning agent from which a liquid crystal alignment film, which is highly able to align liquid crystals, is obtained even when exposed to excessive heating. The liquid crystal aligning agent has a group re...
|
|
WO/2021/054202A1 |
A fluorine-containing ether compound represented by formula (1). (1): R1-R2-CH2-R3-CH2-R4 (In the formula, R1 represents an organic group having an alicyclic structure and from 3 to 13 carbon atoms; R2 represents a group expressed by for...
|
|
WO/2021/052271A1 |
A magnolol derivative and a preparation method therefor and an application thereof. The magnolol derivative has a structure represented by formula (1). The magnolol derivative has good water solubility, is colorless and transparent after...
|
